{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T00:52:31Z","timestamp":1779324751114,"version":"3.51.4"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,7,11]],"date-time":"2021-07-11T00:00:00Z","timestamp":1625961600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,7,11]],"date-time":"2021-07-11T00:00:00Z","timestamp":1625961600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Health Serv Res"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Patients in Alberta, Canada are referred to the United States (US) for proton treatment. The Alberta Ministry of Health pays for the proton treatment and the cost of flights to and from the United States. This study aimed to determine the out-of-pocket expenses incurred by patients or patients\u2019 families.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>An electronic survey was sent to 59 patients treated with proton therapy between January 2008 and September 2019. Survey questions asked about expenses related to travel to the US and those incurred while staying in the US, reimbursement of expenses, and whether any time away from work was paid or unpaid leave.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Seventeen respondents (response rate, 29%) reported expenses of flights for family members (mean, CAD 1886; range CAD 0\u20135627), passports\/visas and other travel costs (mean, CAD 124; range CAD 0\u2013546), accommodation during travel to the US (mean, CAD 50; range CAD 0\u2013563), food during travel to the US (mean, CAD 89; range CAD 0\u2013338), accommodation in the US (rented home\/apartment mean, CAD 7394; range CAD 3075-13,305; hotel mean, CAD 4730; range CAD 3564-5895; other accommodation mean CAD 2660; range CAD 0\u201313,842), transportation in the US (car mean, CAD 2760; range CAD 0\u20137649; bus\/subway mean, CAD 413; range CAD 246\u2013580), and food in the US (mean, CAD 2443; range 0\u20136921). Expenses were partially reimbursed or covered by not-for-profit organizations or government agencies for some patients (35%). Patients missed a mean of 59\u2009days of work; accompanying family members missed an average of 34\u2009days. For 29% this time away from work was paid, but unpaid for 71% of respondents.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Multiple factors contributed to the expenses incurred including age of the patient, number of accompanying individuals, available accommodation, mode of transportation within the US, and whether the patient qualified for financial support. Added to this burden is the potential loss of wages for time away from work. The study showed a large variation in indirect costs for each family and supports actively seeking more opportunities for financial support for families with children with cancer.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12913-021-06701-z","type":"journal-article","created":{"date-parts":[[2021,7,11]],"date-time":"2021-07-11T02:02:12Z","timestamp":1625968932000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Indirect costs associated with out-of-country referral for proton therapy: a survey of adult and pediatric patients in Alberta, Canada"],"prefix":"10.1186","volume":"21","author":[{"given":"Jacqueline","family":"Middleton","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karina","family":"Black","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sunita","family":"Ghosh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David D.","family":"Eisenstat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samir","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,7,11]]},"reference":[{"issue":"2","key":"6701_CR1","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1001\/jamaoncol.2019.4889","volume":"6","author":"B Baumann","year":"2020","unstructured":"Baumann B, Mitra N, Harton J, Xiao Y, Wojcieszynski A, Gabriel P, et al. Comparative effectiveness of proton vs photon therapy as part of concurrent chemoradiotherapy for locally advanced cancer. Jama Oncol. 2020;6(2):237\u201346. https:\/\/doi.org\/10.1001\/jamaoncol.2019.4889.","journal-title":"Jama Oncol"},{"issue":"2","key":"6701_CR2","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1016\/j.ijrobp.2010.11.027","volume":"82","author":"N Boehling","year":"2012","unstructured":"Boehling N, Grosshans D, Bluett J, Palmer M, Song X, Amos R. Dosimetric comparison of three-dimensional conformal proton radiotherapy, intensity-modulated proton therapy, and intensity-modulated radiotherapy for treatment of pediatric craniopharyngiomas. Int J Radiat Oncol Biol Phys. 2012;82(2):643\u201352. https:\/\/doi.org\/10.1016\/j.ijrobp.2010.11.027.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"6701_CR3","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.addr.2016.11.006","volume":"109","author":"R Mohan","year":"2017","unstructured":"Mohan R, Grosshans D. Proton therapy \u2013 present and future. Adv Drug Deliv Rev. 2017;109:26\u201344. https:\/\/doi.org\/10.1016\/j.addr.2016.11.006.","journal-title":"Adv Drug Deliv Rev"},{"key":"6701_CR4","unstructured":"Particle Therapy Co-Operative Group [Web page]. Particle Therapy Facilities in Operation. Available at: http:\/\/www.ptcog.ch\/index.php\/facilities-in-operation. Accessed 4 Dec 2020."},{"issue":"24","key":"6701_CR5","doi-asserted-by":"publisher","first-page":"E664","DOI":"10.1503\/cmaj.190008","volume":"191","author":"D Tsang","year":"2019","unstructured":"Tsang D, Patel S. Proton beam for cancer. Can Med Assoc J. 2019;191(24):E664\u20136. https:\/\/doi.org\/10.1503\/cmaj.190008.","journal-title":"Can Med Assoc J"},{"issue":"5","key":"6701_CR6","doi-asserted-by":"publisher","first-page":"251","DOI":"10.3747\/co.21.2207","volume":"21","author":"S Patel","year":"2014","unstructured":"Patel S, Kostaras X, Parliament M, Olivotto IA, Nordel R, Aronyk K, et al. Recommendations for the referral of patients for proton-beam therapy, an Alberta Health Services report: a model for Canada? Curr Oncol. 2014;21(5):251\u201362. https:\/\/doi.org\/10.3747\/co.21.2207.","journal-title":"Curr Oncol"},{"key":"6701_CR7","unstructured":"Alberta Government [Web page]. Out of country health services funding requests. Available at: https:\/\/www.alberta.ca\/ahcip-out-of-country-health-funding.aspx. Accessed 25 Jan 2021."},{"key":"6701_CR8","doi-asserted-by":"publisher","unstructured":"Iragorri N, de Oliveira C, Fitzgerald N, Essue B. The out-of-pocket cost burden of cancer care\u2014a systematic literature review. Curr Oncol. 2021;28(2):1216\u201348. https:\/\/doi.org\/10.3390\/curroncol28020117.","DOI":"10.3390\/curroncol28020117"},{"issue":"14","key":"6701_CR9","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1001\/jama.1996.03540140060028","volume":"276","author":"LB Russell","year":"1996","unstructured":"Russell LB, Gold MR, Siegel JE, Daniels N, Weinstein MC. The role of cost-effectiveness analysis in health and medicine. JAMA. 1996;276(14):1172\u20137. https:\/\/doi.org\/10.1001\/jama.1996.03540140060028.","journal-title":"JAMA"},{"issue":"1","key":"6701_CR10","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1038\/s41585-019-0258-3","volume":"17","author":"BS Imber","year":"2020","unstructured":"Imber BS, Varghese M, Ehdaie B, Gorovets D. Financial toxicity associated with treatment of localized prostate cancer. Nat Rev Urol. 2020;17(1):28\u201340. https:\/\/doi.org\/10.1038\/s41585-019-0258-3.","journal-title":"Nat Rev Urol"},{"issue":"2","key":"6701_CR11","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.nrl.2016.05.003","volume":"33","author":"J Undabeitia","year":"2018","unstructured":"Undabeitia J, Torres-Bayona S, Sampron N, Arrazola M, Bollar A, Armendariz M, et al. Indirect costs associated with glioblastoma: experience of one hospital. Neurologia. 2018;33(2):85\u201391. https:\/\/doi.org\/10.1016\/j.nrl.2016.05.003.","journal-title":"Neurologia"},{"issue":"4","key":"6701_CR12","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1111\/j.1524-4733.2006.00114.x","volume":"9","author":"R Ernst","year":"2006","unstructured":"Ernst R. Indirect costs and cost effectiveness analysis. Value Health. 2006;9(4):253\u201361. https:\/\/doi.org\/10.1111\/j.1524-4733.2006.00114.x.","journal-title":"Value Health"},{"issue":"7","key":"6701_CR13","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1016\/j.jstrokecerebrovasdis.2014.02.017","volume":"23","author":"H Joo","year":"2014","unstructured":"Joo H, George M, Fang J, Wang G. A literature review of indirect costs associated with stroke. J Stroke Cerebrovasc Dis. 2014;23(7):1753\u201363. https:\/\/doi.org\/10.1016\/j.jstrokecerebrovasdis.2014.02.017.","journal-title":"J Stroke Cerebrovasc Dis"},{"issue":"4","key":"6701_CR14","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1007\/s40273-014-0132-3","volume":"32","author":"M Krol","year":"2014","unstructured":"Krol M, Brouwer W. How to estimate productivity costs in economic evaluations. PharmacoEconomics. 2014;32(4):335\u201344. https:\/\/doi.org\/10.1007\/s40273-014-0132-3.","journal-title":"PharmacoEconomics."},{"key":"6701_CR15","doi-asserted-by":"publisher","unstructured":"Suzana M, Mills A, Tangcharoensathien V, Chongsuvivatwong V. The economic burden of medical treatment: a cross sectional study of Maldivian medical travelers. BMC Health Serv Res. 2015;15:418.\u00a0https:\/\/doi.org\/10.1186\/s12913-015-1054-2.","DOI":"10.1186\/s12913-015-1054-2"},{"issue":"2","key":"6701_CR16","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","volume":"42","author":"PA Harris","year":"2009","unstructured":"Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap) - a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42(2):377\u201381. https:\/\/doi.org\/10.1016\/j.jbi.2008.08.010.","journal-title":"J Biomed Inform"},{"key":"6701_CR17","unstructured":"US Department of State Bureau of Consular Affairs [Web page]. Fees for visa services. Available at: https:\/\/travel.state.gov\/content\/travel\/en\/us-visas\/visa-information-resources\/fees\/fees-visa-services.html#temp. Accessed 29 Oct 2020."},{"key":"6701_CR18","unstructured":"Kids with Cancer [Web page]. What we do. Available from: https:\/\/www.kidswithcancer.ca\/what-we-do\/. Accessed 30 Jun 2020."},{"key":"6701_CR19","unstructured":"Alberta Government [Web page]. Family Support for Children with Disabilities. Available from: https:\/\/www.alberta.ca\/fscd.aspx. Accessed 25 Jun 2020."},{"key":"6701_CR20","unstructured":"Government of Canada [Web page]. Medical Expenses 2019. Available at: https:\/\/www.canada.ca\/en\/revenue-agency\/services\/forms-publications\/publications\/rc4065\/medical-expenses.html. Accessed 30 Oct 2020."},{"key":"6701_CR21","doi-asserted-by":"publisher","unstructured":"Tsang DS, Schulte F. Beyond the brain: Socioeconomic status and race in pediatric brain tumor survivorship. Neuro Oncol. 2021;23(7):1050\u201351. https:\/\/doi.org\/10.1093\/neuonc\/noab079.","DOI":"10.1093\/neuonc\/noab079"},{"issue":"11","key":"6701_CR22","doi-asserted-by":"publisher","first-page":"e3644","DOI":"10.7759\/cureus.3644","volume":"10","author":"WL Smith","year":"2018","unstructured":"Smith WL, Smith CD, Patel S, et al. What conditions make proton beam therapy financially viable in Western Canada? Cureus. 2018;10(11):e3644. https:\/\/doi.org\/10.7759\/cureus.3644.","journal-title":"Cureus"},{"issue":"1","key":"6701_CR23","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1186\/1748-717X-7-167","volume":"7","author":"C Gillan","year":"2012","unstructured":"Gillan C, Briggs K, Pazos A, et al. Barriers to accessing radiation therapy in Canada: a systematic review. Radiat Oncol. 2012;7(1):167\u201375. https:\/\/doi.org\/10.1186\/1748-717X-7-167.","journal-title":"Radiat Oncol"},{"issue":"3","key":"6701_CR24","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1016\/j.ijrobp.2015.06.004","volume":"93","author":"E Liu","year":"2015","unstructured":"Liu E, Santibanez P, Puterman M, et al. A quantitative analysis of the relationship between radiation therapy use and travel time. Int J Radiat Oncol Biol Phys. 2015;93(3):710\u20138. https:\/\/doi.org\/10.1016\/j.ijrobp.2015.06.004.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"6701_CR25","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1016\/j.ijrobp.2014.04.011","volume":"89","author":"P Santibanez","year":"2014","unstructured":"Santibanez P, Gaudet M, French J, Liu E, Tyldesley S. Optimal location of radiation therapy centers with respect to geographic access. Int J Radiat Oncol Biol Phys. 2014;89(4):745\u201355. https:\/\/doi.org\/10.1016\/j.ijrobp.2014.04.011.","journal-title":"Int J Radiat Oncol Biol Phys"}],"container-title":["BMC Health Services Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-021-06701-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12913-021-06701-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-021-06701-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,11]],"date-time":"2021-07-11T02:02:18Z","timestamp":1625968938000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmchealthservres.biomedcentral.com\/articles\/10.1186\/s12913-021-06701-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,11]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["6701"],"URL":"https:\/\/doi.org\/10.1186\/s12913-021-06701-z","relation":{},"ISSN":["1472-6963"],"issn-type":[{"value":"1472-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,11]]},"assertion":[{"value":"23 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethics approval was obtained from the Health Research Ethics Board of Alberta-Cancer Committee (HREBA.CC-18-0590). The introductory cover letter and survey were reviewed and approved by the ethics committee. The ethics committee approved a waiver of consent for this minimal risk study. All methods were carried out in accordance with relevant guidelines and regulations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"683"}}